SEC Form 4 · accession 0001209191-19-009989
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carlo de Notaristefani
Officer — Executive VP Global Operations
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 7:43 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 12, 2019 | A | 14,432 | — | A | 17,162 | D | |
| Ordinary SharesF1,F4,F5 | Feb 13, 2019 | S | 5,041 | $17.875 | D | 12,121 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF6,F7,F1 | — | Feb 12, 2019 | A | 1,204 | A | — | — | Ordinary Shares | 1,204 | 1,204 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units.
- F3The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the performance share units.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $17.88, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F7Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time based vesting and will vest on May 16, 2019.